Abstract

Ophthalmic immune-related adverse events occur at a lower frequency than other immune-related adverse events, in part due to the immune privilege of the eye. Their severity can range from mild and not requiring specific treatment to severe, requiring discontinuation of the medication as well as management with systemic immunosuppressive medications. The spectrum of events can involve all structures of the eyes, with keratoconjunctivitis sicca and uveitis being the two most common ocular manifestations. This chapter will review the epidemiology, clinical presentations, evaluation, management, and prognosis for patients with ophthalmic adverse events of immune checkpoint inhibition.

Original languageEnglish (US)
Title of host publicationManaging Immunotherapy Related Organ Toxicities
Subtitle of host publicationA Practical Guide
PublisherSpringer International Publishing
Pages231-253
Number of pages23
ISBN (Electronic)9783031002410
ISBN (Print)9783031002403
DOIs
StatePublished - Jan 1 2022

Keywords

  • Conjunctivitis
  • Episcleritis
  • Giant cell arteritis
  • Keratitis
  • Myasthenia gravis
  • Ophthalmic
  • Optic neuropathy
  • Orbital inflammation
  • Retinal detachment
  • Scleritis
  • Thyroid eye disease
  • Uveitis
  • Vasculitis

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint

Dive into the research topics of 'Ophthalmology (Eye)'. Together they form a unique fingerprint.

Cite this